Ozempic and GLP-1: Health Benefits Beyond Weight Loss

Ozempic has become one of the most talked-about medicines in the world. Originally developed to help manage type 2 diabetes, it has attracted enormous attention because of its effects on appetite, body weight and metabolic health.

But the most interesting development may not be weight loss alone.

Research suggests that semaglutide, the active ingredient in Ozempic and Wegovy, can offer important benefits for certain people with cardiovascular disease, chronic kidney disease and other metabolic conditions.

Does that make GLP-1 medication a breakthrough for healthy ageing? Possibly in some areas, but the evidence needs to be interpreted carefully.

From a natural health perspective, I believe these medicines are best understood as powerful medical tools that can complement nutritious eating, physical activity and long-term lifestyle changes. They are not substitutes for these foundations.

What Is GLP-1?

GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally released by the intestines after eating.

GLP-1 helps regulate several important functions:

• Stimulating insulin release when blood glucose is elevated.
• Reducing inappropriate glucagon release.
• Slowing stomach emptying.
• Influencing appetite and feelings of fullness.
• Helping regulate blood glucose after meals.

Medicines known as GLP-1 receptor agonists mimic aspects of this natural hormone’s activity.

Unlike the body’s own GLP-1, which is rapidly broken down, medicines such as semaglutide have been designed to remain active much longer.

What Is Ozempic?

Ozempic is a prescription medicine containing semaglutide, administered as a once-weekly injection.

In Australia, Ozempic is approved for adults with insufficiently controlled type 2 diabetes. It also has an approved indication to reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.

Although Ozempic can produce weight loss, it is important to distinguish it from Wegovy, another semaglutide product specifically approved for chronic weight management in eligible patients.

Ozempic, Wegovy and Mounjaro: What’s the Difference?

Although Ozempic and Wegovy contain the same active ingredient, their approved uses and dosing regimens differ.

Mounjaro works through two hormone receptors and has produced greater average weight loss than semaglutide in some comparative studies. However, individual results and tolerability vary.

1. Weight Loss and Appetite Control

One of the most noticeable effects of GLP-1 medicines is reduced appetite.

Many people report feeling satisfied with smaller meals, experiencing fewer cravings and thinking less frequently about food.

Semaglutide acts on appetite-regulating pathways in the brain and slows gastric emptying.

How Much Weight Can People Lose?

In the STEP 1 clinical trial, adults with overweight or obesity but without diabetes lost approximately 14.9% of their starting body weight after 68 weeks with semaglutide 2.4 mg, compared with approximately 2.4% with placebo. Both groups received lifestyle intervention.

These results were achieved with the weight-management dose studied for Wegovy, not the lower starting doses commonly used with Ozempic.

Weight loss varies considerably between individuals, and some people lose much less than the trial average.

2. Better Blood Sugar Control

Semaglutide improves blood glucose regulation through several mechanisms.

It stimulates insulin secretion in a glucose-dependent manner and reduces glucagon secretion when appropriate.

For people with type 2 diabetes, it can substantially reduce HbA1c, a measure of average blood glucose over approximately three months.

When used alone, semaglutide has a relatively low risk of hypoglycaemia. However, that risk increases when combined with insulin or certain diabetes medicines such as sulfonylureas.

3. Cardiovascular Benefits: One of the Most Important Discoveries

Cardiovascular disease remains a major cause of illness and premature death.

Clinical trials have demonstrated that semaglutide can reduce major cardiovascular events in selected high-risk populations.

The SELECT Trial

The SELECT trial included more than 17,000 adults with established cardiovascular disease and overweight or obesity, but without diabetes.

Participants received either semaglutide 2.4 mg weekly or placebo, alongside usual care.

During follow-up, a major cardiovascular event occurred in:

• 6.5% of participants receiving semaglutide.
• 8.0% of participants receiving placebo.

This represented approximately a 20% relative reduction in the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The absolute difference was approximately 1.5 percentage points over the study period.

This is clinically meaningful evidence, but it applies to a defined population with existing cardiovascular disease and should not be interpreted as proof that semaglutide prevents heart attacks in all healthy adults.

4. Kidney Protection

Another important development involves kidney disease.

The FLOW trial investigated semaglutide in adults with type 2 diabetes and chronic kidney disease.

Participants receiving semaglutide experienced a 24% relative reduction in a composite outcome involving major kidney disease events or cardiovascular death.

The study also found slower average deterioration in estimated kidney filtration function.

These findings support the use of semaglutide in appropriately selected patients with diabetic kidney disease.

However, kidney protection in these patients does not mean the medicine is free of kidney-related risks.

Severe vomiting, diarrhoea and dehydration can sometimes cause acute kidney injury, even in people without known kidney disease.

5. Blood Pressure and Metabolic Health

Weight reduction can improve several cardiovascular and metabolic risk factors.

Semaglutide studies have reported average reductions in systolic blood pressure, although the effect varies.

Some people also experience improvements in waist circumference, blood glucose and certain lipid measures.

These changes may contribute to better overall metabolic health.

Nevertheless, GLP-1 medicines should not automatically replace prescribed blood pressure or cholesterol treatment.

6. Fatty Liver Disease and MASH

Metabolic dysfunction-associated steatotic liver disease, previously commonly called fatty liver disease, is associated with obesity, insulin resistance and other metabolic risk factors.

A more advanced inflammatory form is called metabolic dysfunction-associated steatohepatitis, or MASH.

Clinical studies have found that semaglutide can improve certain liver outcomes in selected patients with MASH.

In Australia, Wegovy has a provisionally approved indication for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis.

This is not the same as recommending Ozempic for every person with fatty liver disease.

Appropriate diagnosis, fibrosis assessment and specialist advice remain important.

7. Heart Failure Symptoms

Research has also examined semaglutide in people with obesity-related heart failure with preserved ejection fraction, commonly called HFpEF.

Clinical trials have shown improvements in certain measures of symptoms, physical limitations and exercise capacity.

These findings are encouraging because excess body weight can contribute to this form of heart failure.

However, treatment decisions should depend on the specific type of heart failure and the patient’s overall medical condition.

8. Does Ozempic Reduce Inflammation?

Some studies have reported reductions in inflammatory markers, including C-reactive protein, during semaglutide treatment.

These changes may reflect weight loss, improved metabolic function and potentially other biological effects.

However, lower inflammatory markers do not establish that Ozempic treats autoimmune diseases such as rheumatoid arthritis.

It should not replace disease-modifying antirheumatic medication or other prescribed anti-inflammatory treatment.

9. Could GLP-1 Medicines Support Brain Health?

Researchers are investigating whether GLP-1 receptor agonists may influence brain inflammation, energy metabolism and neurological disease processes.

Observational studies and early research have raised questions about possible effects on dementia and other neurological conditions.

However, encouraging laboratory findings or associations do not prove clinical benefit.

Semaglutide is not an established treatment for Alzheimer’s disease, memory loss or Parkinson’s disease.

Claims that Ozempic prevents dementia should therefore be treated cautiously.

10. GLP-1 Medicines and Healthy Ageing

There is increasing interest in whether GLP-1 medicines might support healthier ageing by improving metabolic and cardiovascular risk factors.

Reducing obesity, improving diabetes control and lowering cardiovascular risk may help some people remain healthier for longer.

However, there is no established evidence that Ozempic directly slows biological ageing or extends lifespan in otherwise healthy humans.

The most convincing benefits remain those demonstrated in clinical trials for specific medical conditions.

11. Important Side Effects of Ozempic

Like all prescription medicines, Ozempic can cause adverse effects.

Common Side Effects

• Nausea.
• Vomiting.
• Diarrhoea.
• Constipation.
• Abdominal discomfort.
• Bloating or reflux.
• Reduced appetite.

Digestive symptoms are often more noticeable when treatment begins or the dose increases.

Less Common but Important Risks

• Acute pancreatitis.
• Gallbladder disease, including gallstones.
• Dehydration and acute kidney injury.
• Severe gastrointestinal symptoms or delayed gastric emptying.
• Hypoglycaemia when combined with certain diabetes medicines.
• Worsening diabetic retinopathy in some susceptible patients.
• Rare serious visual complications, including non-arteritic anterior ischaemic optic neuropathy.

Sudden vision loss requires urgent medical assessment.

Severe persistent abdominal pain, particularly with vomiting, also requires prompt assessment because it may indicate pancreatitis or another serious condition.

Semaglutide is generally avoided in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, consistent with relevant prescribing precautions.

It is not recommended during pregnancy and must be stopped sufficiently in advance of a planned pregnancy according to prescribing guidance.

12. GLP-1 Medicines and Surgery

GLP-1 medicines slow gastric emptying.

This can increase the risk of stomach contents remaining present during general anaesthesia or deep sedation, even after standard fasting.

Always tell your surgeon, anaesthetist and procedural team if you use Ozempic, Wegovy or Mounjaro.

Do not independently stop or restart medication before surgery. Follow your treating team’s individual instructions.

13. Protecting Muscle During Weight Loss

Weight loss involves changes in both fat mass and lean mass.

Some people taking GLP-1 medicines may lose a meaningful amount of muscle, particularly if protein intake and resistance exercise are inadequate.

This is especially important for older adults, because muscle strength supports balance, mobility and independence.

How to Support Muscle Health

• Include protein-rich foods in regular meals.
• Continue resistance training where appropriate.
• Avoid excessively restrictive diets.
• Maintain sufficient fluid intake.
• Monitor strength and physical function, not just body weight.
• Discuss nutritional support with a dietitian if appetite is very low.

Creatine monohydrate may support strength-training performance in suitable individuals, but it does not replace adequate protein or exercise.

14. What Should You Eat While Taking Ozempic?

Because appetite may be reduced, nutritional quality becomes particularly important.

Smaller, balanced meals are often better tolerated than large, high-fat meals.

Foods to Prioritise

• Fish, eggs, lean meat, tofu and legumes for protein.
• Vegetables and fruit for fibre and micronutrients.
• Whole grains in portions that are comfortable to digest.
• Yoghurt and other nutritious dairy or fortified alternatives.
• Healthy fats from olive oil, nuts and seeds.
• Water and other suitable fluids.

If nausea is troublesome, smaller meals, eating slowly and avoiding very rich foods may help.

Persistent vomiting, inability to maintain hydration or severe abdominal pain requires medical advice.

15. Do You Need Supplements While Taking GLP-1 Medication?

There is no universal supplement regimen required for everyone using Ozempic.

However, reduced food intake may make it harder for some people to meet nutritional requirements.

Supplements should address genuine dietary or clinical needs rather than being added automatically.

16. What Happens When You Stop Ozempic?

Appetite often increases after GLP-1 treatment is discontinued.

Clinical studies show that substantial weight regain is common after stopping semaglutide, particularly without ongoing support.

This does not mean everyone regains all their lost weight, but it highlights that obesity is often a chronic condition requiring long-term management.

People considering stopping treatment should discuss a maintenance strategy with their prescriber.

17. Ozempic and Mounjaro: Which Produces More Weight Loss?

Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors.

Head-to-head research in adults with obesity has shown greater average weight loss with tirzepatide than semaglutide at the doses compared.

However, weight loss is only one factor when choosing treatment.

Other considerations include:

• Approved indication.
• Cardiovascular or kidney disease.
• Side effects.
• Other medications.
• Cost and availability.
• Individual response.

A medication that produces greater average weight loss is not automatically the best choice for every patient.

18. Who Might Benefit Most from GLP-1 Treatment?

GLP-1 treatment may be particularly valuable for appropriately selected adults with:

• Type 2 diabetes requiring improved glucose control.
• Obesity or overweight with relevant health complications.
• Established cardiovascular disease and an indication supported by clinical evidence.
• Type 2 diabetes with chronic kidney disease.
• Certain other conditions covered by approved indications and specialist recommendations.

People without a recognised medical indication should not assume that taking semaglutide will provide the same benefits seen in clinical trials.

Frequently Asked Questions

Does Ozempic have health benefits besides weight loss?

Yes. Semaglutide improves blood glucose control and has demonstrated cardiovascular and kidney benefits in selected high-risk populations.

Does Ozempic reduce the risk of heart attacks?

Semaglutide has reduced major cardiovascular events in clinical trials involving specific groups, including people with established cardiovascular disease. The size of benefit depends on the population and treatment regimen.

Can Ozempic protect your kidneys?

In adults with type 2 diabetes and chronic kidney disease, semaglutide reduced important kidney-related outcomes in the FLOW trial. This does not mean it prevents all kidney disease.

Does Ozempic help with fatty liver?

Semaglutide has shown benefits in certain studies of metabolic liver disease. Wegovy has an Australian indication for selected patients with MASH, but specialist assessment is necessary.

Does Ozempic reduce inflammation?

Some studies report improvements in inflammatory markers, but Ozempic is not an established treatment for autoimmune inflammatory diseases.

Can Ozempic prevent Alzheimer’s disease?

No. There is currently insufficient evidence to recommend semaglutide for preventing or treating Alzheimer’s disease.

Can older adults use Ozempic?

Age alone does not necessarily prevent treatment, but older adults require careful attention to nutrition, hydration, muscle preservation, medications and overall frailty risk.

Is Ozempic the same as Mounjaro?

No. Ozempic contains semaglutide and targets GLP-1 receptors. Mounjaro contains tirzepatide and targets both GIP and GLP-1 receptors.

Do you have to take Ozempic forever?

Not necessarily. Duration depends on the medical indication, effectiveness, side effects and treatment goals. Weight regain after discontinuation is common, so long-term planning is important.

Final Thoughts: My Natural Health Perspective

GLP-1 medicines represent a significant advance in the treatment of type 2 diabetes and obesity.

Their potential benefits extend beyond weight loss, with substantial evidence for cardiovascular and kidney protection in certain patient groups.

There is also encouraging research involving fatty liver disease, heart failure symptoms and other metabolic conditions.

However, these medicines are not miracle anti-ageing treatments, and their benefits must be balanced against gastrointestinal side effects, nutritional risks and other precautions.

My preferred approach is to use GLP-1 medication when medically appropriate while protecting muscle through resistance exercise, eating nutritious protein-rich meals, maintaining hydration and monitoring long-term metabolic health.

Successful treatment should be measured not simply by kilograms lost, but by improvements in health, physical function and quality of life.

References and Further Reading

• Therapeutic Goods Administration – Ozempic Kidney Indication
• Healthdirect Australia – Ozempic
• SELECT Trial – Semaglutide and Cardiovascular Outcomes
• FLOW Trial – Semaglutide and Chronic Kidney Disease
• STEP 1 Trial – Semaglutide and Weight Loss
• TGA – GLP-1 and Dual GIP/GLP-1 Medicine Safety
• Heart Foundation Australia – Obesity and Cardiovascular Disease

Medical disclaimer: This article provides general educational information and is not a substitute for professional medical advice. Ozempic, Wegovy and Mounjaro are prescription medicines. Treatment selection, dosing and monitoring should be managed by an appropriately qualified healthcare professional. Never change or stop prescribed medication without medical advice.